<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns:mv="http://macVmlSchemaUri" xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta name=Title content="">
<meta name=Keywords content="">
<meta http-equiv=Content-Type content="text/html; charset=macintosh">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 14">
<meta name=Originator content="Microsoft Word 14">
<link rel=File-List href="BYSI%201E%20-%20191025_files/filelist.xml">
<link rel=Edit-Time-Data href="BYSI%201E%20-%20191025_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Microsoft Office User</o:Author>
  <o:LastAuthor>Luca Donà</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>81</o:TotalTime>
  <o:Created>2019-10-30T17:10:00Z</o:Created>
  <o:LastSaved>2019-10-30T17:10:00Z</o:LastSaved>
  <o:Pages>2</o:Pages>
  <o:Words>964</o:Words>
  <o:Characters>5497</o:Characters>
  <o:Lines>45</o:Lines>
  <o:Paragraphs>12</o:Paragraphs>
  <o:CharactersWithSpaces>6449</o:CharactersWithSpaces>
  <o:Version>14.0</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData href="BYSI%201E%20-%20191025_files/themedata.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>150</w:Zoom>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>JA</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
  DefSemiHidden="true" DefQFormat="false" DefPriority="99"
  LatentStyleCount="276">
  <w:LsdException Locked="false" Priority="0" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>
  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" Priority="10" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" Priority="11" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" Priority="22" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="false"
   UnhideWhenUsed="false" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="false" UnhideWhenUsed="false"
   Name="Note Level 1"/>
  <w:LsdException Locked="false" SemiHidden="false" UnhideWhenUsed="false"
   Name="Note Level 2"/>
  <w:LsdException Locked="false" SemiHidden="false" UnhideWhenUsed="false"
   Name="Note Level 3"/>
  <w:LsdException Locked="false" SemiHidden="false" UnhideWhenUsed="false"
   Name="Note Level 4"/>
  <w:LsdException Locked="false" SemiHidden="false" UnhideWhenUsed="false"
   Name="Note Level 5"/>
  <w:LsdException Locked="false" SemiHidden="false" UnhideWhenUsed="false"
   Name="Note Level 6"/>
  <w:LsdException Locked="false" SemiHidden="false" UnhideWhenUsed="false"
   Name="Note Level 7"/>
  <w:LsdException Locked="false" SemiHidden="false" UnhideWhenUsed="false"
   Name="Note Level 8"/>
  <w:LsdException Locked="false" SemiHidden="false" UnhideWhenUsed="false"
   Name="Note Level 9"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
@font-face
	{font-family:"Courier New";
	panose-1:2 7 3 9 2 2 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
	{font-family:Times;
	panose-1:2 0 5 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Wingdings;
	panose-1:2 0 5 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Wingdings;
	panose-1:2 0 5 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-520092929 1073786111 9 0 415 0;}
@font-face
	{font-family:"Lucida Grande";
	panose-1:2 11 6 0 4 5 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-520090897 1342218751 0 0 447 0;}
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-priority:99;
	mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.25in right 6.5in;
	font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-priority:99;
	mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.25in right 6.5in;
	font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
span.MsoPageNumber
	{mso-style-priority:99;
	mso-ansi-font-size:10.0pt;
	font-family:Times;
	mso-ascii-font-family:Times;
	mso-hansi-font-family:Times;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:#0563C1;
	mso-themecolor:hyperlink;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:#954F72;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Lucida Grande";
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
span.UnresolvedMention1
	{mso-style-name:"Unresolved Mention1";
	mso-style-noshow:yes;
	mso-style-priority:99;
	color:#605E5C;
	background:#E1DFDD;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Balloon Text";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Lucida Grande";
	mso-ascii-font-family:"Lucida Grande";
	mso-hansi-font-family:"Lucida Grande";
	mso-bidi-font-family:"Lucida Grande";}
span.UnresolvedMention2
	{mso-style-name:"Unresolved Mention2";
	mso-style-noshow:yes;
	mso-style-priority:99;
	color:#605E5C;
	background:#E1DFDD;}
span.UnresolvedMention3
	{mso-style-name:"Unresolved Mention3";
	mso-style-noshow:yes;
	mso-style-priority:99;
	color:#605E5C;
	background:#E1DFDD;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Footer;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Header;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
 /* Page Definitions */
@page
	{mso-footnote-separator:url(":BYSI 1E - 191025_files:header.htm") fs;
	mso-footnote-continuation-separator:url(":BYSI 1E - 191025_files:header.htm") fcs;
	mso-endnote-separator:url(":BYSI 1E - 191025_files:header.htm") es;
	mso-endnote-continuation-separator:url(":BYSI 1E - 191025_files:header.htm") ecs;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-even-footer:url(":BYSI 1E - 191025_files:header.htm") ef1;
	mso-footer:url(":BYSI 1E - 191025_files:header.htm") f1;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
@list l0
	{mso-list-id:921137028;
	mso-list-type:hybrid;
	mso-list-template-ids:-1285637366 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1
	{mso-list-id:1839881676;
	mso-list-type:hybrid;
	mso-list-template-ids:1761657132 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->
</head>

<body bgcolor=white lang=EN-US link="#0563C1" vlink="#954F72" style='tab-interval:
.5in'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:18.0pt;font-family:
Times'>Elle Investments Research Report: BYSI<o:p></o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;font-family:
Times'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Company:
<span class=SpellE>BeyondSpring</span><span style='mso-tab-count:3'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>
<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Symbol:
<b style='mso-bidi-font-weight:normal'>BYSI</b><span style='mso-tab-count:3'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style="mso-spacerun:yes">&nbsp; </span><span
style="mso-spacerun:yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Analysis
Date: 10/25/19<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Analysis
Price: $12.28<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Price
Target (PT): $25.00<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Upside:
<b style='mso-bidi-font-weight:normal'>104%</b><o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Dividend:
NA<span style='mso-tab-count:5'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>
<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Recommendation:
<b style='mso-bidi-font-weight:normal'>Buy</b><span style='mso-tab-count:2'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style="mso-spacerun:yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><b
style='mso-bidi-font-weight:normal'><span style='font-size:14.0pt;font-family:
Times'>BYSI: 1-Year Chart<o:p></o:p></span></b></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-family:Times;mso-no-proof:yes'><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:468pt;height:115pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="BYSI%201E%20-%20191025_files/image001.png" o:title=""/>
</v:shape><![endif]--><![if !vml]><img width=470 height=117
src="BYSI%201E%20-%20191025_files/image002.png" v:shapes="Picture_x0020_3"><![endif]></span><span
style='font-family:Times'><o:p></o:p></span></p>

<p class=MsoNormal align=center style='text-align:center;tab-stops:276.2pt'><span
style='font-size:10.0pt;font-family:Times'>Source: Seeking Alpha<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>INVESTMENT THESIS:</span></b><span
style='font-family:Times'> <o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>The
recent capital raise that sent BYSI’s stock down over 20% offers a great entry
point for new investors. NDAs for lead candidate Plinabulin in both the US and
China are set to be submitted during 2020, meaning that commercialization is
right around the corner. An improved safety profile demonstrated thus far
indicate that Plinabulin should be able to differentiate itself in a crowded
CIN field. Additionally, its anti-cancer properties could potentially position
it to be a part of not just NSCLC combo therapies, but across various tumor
types. We think BYSI is a Buy.<span style="mso-spacerun:yes">&nbsp;&nbsp;
</span><o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>LIQUIDITY POSITION:</span></b><span
style='font-family:Times'> Excellent<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>As
of 2Q19 (ended June 30 and announced on September 18), BYSI had a cash balance
of $1M. During June and July, BYSI received about $10M from the sale of certain
equity interests in their partially-owned Chinese subsidiary Dalian <span
class=SpellE>Wanchunbulin</span> Pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>On
July 17 they completed an offering, selling approximately 2.1M shares @
$17.00/share for gross proceeds of $35M. (Note: The closing price on July 16
was $19.11/share, representing a discount of 11%).<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>On
October 25 they announced the terms of another offering, pricing approximately
1.9M shares @ $13.50/share for gross proceeds of $25M. With the stock closing on
October 24 at a price of $16.77/share, this represents a discount of almost
20%, which explains the big move downward.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>These
transactions together bring their cash balance to about $71M. However, with 3Q19
having just ended, their cash balance is likely down to $64M as of September
30. Considering that the quarterly cash burn is about $7M, they have a solid
cash runway of at least 9 quarters.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>COMMERCIAL PROSPECTS:</span></b><span
style='font-family:Times'> Excellent<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>Plinabulin</span></b><span
style='font-family:Times'><o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Value: $436M<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Neutropenia
is the condition that is characterized by having fewer than normal white blood
cells. As well as killing off bad cancer cells, the radiation from chemotherapy
unfortunately also harms disease-fighting white bloods cells, which leaves patients
more susceptible to infection.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Amgen’s
(AMGN) <span class=SpellE>Neulasta</span> is a drug that is a man-made form of
a naturally produced substance called G-CSF. G-CSF drugs work by stimulating
the growth of a type of white blood cell called neutrophils, which play a very
important role in fighting infection. <span class=SpellE>Neulasta</span>, which
was launched in 2002, has been very successful at boosting white blood cell
counts in chemo patients. In 2014 it generated worldwide net sales of $4.6B.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>In
2018 the CIN market became more crowded due to the launch of several
biosimilars that were hoping to underprice <span class=SpellE>Neulasta</span>
and take market share. However, Plinabulin is hoping to differentiate itself
from this crowded field. While <span class=SpellE>Neulasta</span> and the
biosimilars are very efficacious, they do come with a harmful side effect: <span
class=SpellE>Neulasta</span> causes bone pain in about 60% of patients, and
severe bone pain in about 25% of patients. Plinabulin, on the other hand, does
not cause any bone pain after day 3 of use as a monotherapy. And when used in
combination with <span class=SpellE>Neulasta</span>, it has proven to be able
to lessen the bone pain compared with <span class=SpellE>Neulasta</span> as a
monotherapy. We feel that being able to match the efficacy of <span
class=SpellE>Neulasta</span> as well as offer an improved tolerability profile
is a compelling value proposition.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Additionally,
Plinabulin has demonstrated anti-cancer properties (in contrast to <span
class=SpellE>Neulasta</span>). It’s currently being tested as a combo therapy
with docetaxel in a phase 3 trial for NSCLC (2<sup>nd</sup> and 3<sup>rd</sup>
line). However, this indication is only a small part of the global oncology
market. The hope is that Plinabulin’s anti-cancer properties can open the door
to potentially being used in combination with other cancer-fighting agents
across many different tumor types.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>Over
the next 12 months, BYSI will have several catalysts that can propel the stock
higher. By the end of 1Q20, lead candidate Plinabulin will have three phase 3
data readouts. They then plan on submitting the NDA for Plinabulin in China for
NSCLC and CIN at some point during 1Q20. The NDA in the US (also for NSCLC and
CIN) will be submitted sometime during 2020.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>Remaining pipeline assets<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Value: none assigned<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>The
remaining pipeline assets are in the preclinical phase. We have not assigned
them any value.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>CONCLUSION:</span></b><span
style='font-family:Times'> <o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>The
drop from the recent capital raise offers a great entry point, as BYSI is now
well-capitalized to see itself through the next two years, give or take. Lead
candidate Plinabulin has thus far demonstrated equivalent efficacy to
multi-blockbuster <span class=SpellE>Neulasta</span> in the CIN space. While
cheaper biosimilars have crowded the market, Plinabulin’s improved safety
profile leads us to believe that it has a good chance of differentiating itself
from the competition. We think BYSI is a Buy.<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><span
style="mso-spacerun:yes">&nbsp;</span><span
style="mso-spacerun:yes">&nbsp;</span><o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'>GLOSSARY:<o:p></o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><b style='mso-bidi-font-weight:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>CIN:
chemotherapy-induced neutropenia<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>G-CSF:
granulocyte colony-stimulating factor<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>NDA:
new drug application<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'>NSCLC:
non-small cell lung cancer<o:p></o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Note: Additional commentary from Elle
Investments can be found at </span></i><a href="http://elle-investments.com"><i
style='mso-bidi-font-style:normal'><span style='font-family:Times'>http://elle-investments.com</span></i></a><i
style='mso-bidi-font-style:normal'><span style='font-family:Times'>. We welcome
your feedback. Additionally, we are thinking of launching a subscription
service that would offer early access to our research, along with some other
features that investors might find useful (i.e. general portfolio management
strategies, live blog updates highlighting our reaction to breaking news,
etc.). If you would be interested in subscribing to such a service, please let
us know.<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Published By: Elle Investments Research
Team<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Phone: (914) 715-8066<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Email: info@elle-investments.com<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'>Disclaimer: The Elle Investments
portfolio is managed utilizing a “<span class=SpellE>quantamental</span>”
approach where each position, while based on Fundamental Analysis, is sized as
part of a larger quantitative portfolio. The commentary presented here is for
research purposes only and is not to be taken as investment advice. Readers are
expected to perform their own due diligence and/or hire an investment
professional prior to entering/exiting positions. Published research ideas are
related to the specific market price and publicly available information at the
time of research submission/publication. Elle Investments will enter/exit
positions without notice.<o:p></o:p></span></i></p>

<p class=MsoNormal style='tab-stops:276.2pt'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal style='tab-stops:276.2pt'><i style='mso-bidi-font-style:
normal'><span style='font-family:Times'><o:p>&nbsp;</o:p></span></i></p>

</div>

</body>

</html>
